Nitrosamine Impurities Affecting Drug-Drug Interaction Studies – Learn More

Adaptive Trial Designs

Flexibility of Adaptive Early Phase Study Designs

Sabina Paglialunga, PhD   Director, Scientific Affairs

Adaptive clinical trials are characterized by innovative and flexible designs that incorporate safety and other information acquired during a study to instruct the next steps in a trial. Typically, these pre-planned adjustments include sample size refinement, subsequent dose level selection, or allocation ratio. In the case of patient studies, adaptive elements may consist of inclusion/exclusion criteria adjustment or stopping rules based on success or lack of efficacy [1].  Adaptive study designs are well established for cancer trials [2], and while they are applied to a lesser degree in other indications, a limited search in revealed nearly 95 non-oncology industry sponsored adaptive trials over the past decade. 

Regulatory Perspective on Adaptive Designs

As interest in flexible design elements grows across all indications, both the FDA and EMA have issued updated guidance on adaptive trial designs for drugs and biologics in recent years [3, 4]. For early phase exploratory studies, the FDA touts the advantages of an adaptive design that advises dosing, pharmacokinetic (PK) and pharmacodynamic (PD) responses, which may improve the design and possibly the chances of success of later-phase trials [3]. 

Adaptive Early Clinical Trial Designs

For single ascending dose (SAD) and multiple ascending dose (MAD) studies, adaptive design elements can be incorporated into the study protocol to add flexibility. This can be a valuable approach when there are still many unknowns in the initial clinical drug development phases. Case examples of recent adaptive protocols are highlighted in Table 1. These elements, such as alterations to drug dose, number of cohorts, or schedules of PK sampling and PD assessments, must be pre-specified in the protocol. For each adaptable component, limits should be set to address any safety concerns and to operate within acceptable risk parameters [5]. For example, if a blood sample schedule can be adjusted to optimize evaluable PK or PD data, the maximum number of blood draws should be noted in the protocol and not exceeded. 

Table 1. Case Studies of Early Clinical Trial Adaptive Study Designs

Case StudyStudy DesignAdaptive ElementsImplementation
Adaptive Dose and PK2-part SAD and MAD study in healthy volunteersDrug dose, infusion volume and/or rate, PK schedule (time points and number of samples)Adaptive elements were modified based on AEs, clinical finding, safety and tolerability resultsProtocol allowed for reduced PK sample number if data permitted 
Adaptive Cohort NumberSAD study in healthy volunteersCohort number and dose levels defined for groups 1-5 Option to add up to 2 additional cohorts Upon review of cohort 1-5 safety and PK data, the decision will be taken to continue with increased dose levels, or an intermediate dose, or to cancel cohorts 6-7  
Adaptive PD ResponseMAD study in participants with obesityNumber of PD assessments Multiple PD assessments evaluated in cohort 1 with option to omit or adjust PD schedule in subsequent cohorts Protocol also indicated the maximum number of PD assessments that can be taken
Adaptive Sample SizeFixed-dose combination vs free dose cross-over bioequivalence (BE) study in healthy volunteersSample size re-estimation Clinical study activity paused during COVID-19 pandemic before all participants completed cross-over scheme  Adaptive and interim analysis was performed to re-evaluate  study sample size and power, using a validated method for crossover BE design [6]. Trial results demonstrated BE based on completed participant data [7]

Advantages of Adaptive Early Clinical Trials

With pre-defined adaptive protocol elements, no amendments are required, which can save time and result in scheduling efficiencies. In the case of future pandemic outbreaks or other extraordinary situations, adaptive designs can serve as a mitigation step and potentially ‘save’ a study from timely delays or the need to repeat the trial. This approach was applied in a BE study, where sample size was re-assessed midway through trial conduct using validated statistical methods to complete the trial without further interruption from a COVID-19 outbreak [7]. Ultimately, the advantage of adaptive, early clinical trial designs can lead to both time and costs savings. Celerion’s Protocol Design and Development Scientists are trial experts and can design early clinical trials with flexible and adaptive elements to get the most out of a study, for less.


1. Pallmann P et al. BMC Med. 2018;16(1):29.   

2. Bothwell LE et al. BMJ Open. 2018;8(2):e018320.

3. Food and Drug Administration. Adaptive Designs for Clinical Trials of Drugs and Biologics  Guidance for Industry. 2019.   

4. European Medicines Agency. Adaptive Pathways.    

5. Lorch U et al. BMC Med Res Methodol. 2014;14:84.   

6. Potvin D et al. Pharm Stat. 2008;7(4):245-62.   

7. Csonka D et al. Pharmacol Res Perspect. 2021;9(5):e00846.